TransMolecular

Quick facts

Phase 2 pipeline

• 131-I-TM-601 · Oncology
  131-I-TM-601 is a targeted alpha-particle therapy that selectively targets and destroys cancer cells.

Phase 1 pipeline

• 131I-TM-601
• TM-601

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• TransMolecular portfolio CI brief
• TransMolecular pipeline updates RSS